MetaCap

Corbus Pharmaceuticals Holdings Inc. (CRBP)

NASDAQ: CRBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.06-0.375 (-15.40%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CRBP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$42.45M
EPS (TTM)
-$6.04
52-week range
2.01 – 12.88
Day range
2.01 – 2.45
Volume / Avg
1.38M / 1.11M
Beta
—

52-week range

$2.01$12.88

CRBP stock today

Shares of Corbus Pharmaceuticals (CRBP) finished lower on Nov 20 at $2.06, a drop of 15.40% or $0.375 per share, versus the S&P 500's 3.70% decline. Shares are 84.0% below their 52-week high of $12.88, set on May 22, 2026 and 2.5% above the 52-week low of $2.01, near the bottom of the past year's range. CRBP is down 74.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 82.8%.

Corbus Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$6.04), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Corbus Pharmaceuticals

Company profile

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Yuval Cohen Ph.D.
Headquarters
Norwood, MA
Employees
36

Financial highlights

Full financials

Corbus Pharmaceuticals reported a net loss of $78.5 million, compared with a loss of $40.2 million a year earlier. Diluted earnings per share came in at -$5.90.

Corbus Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue———$0$881.71K
Growth———-100.00%-77.61%
Net income$-78.54M$-40.21M$-44.60M$-42.35M$-45.64M
EPS (diluted)$-5.90$-3.68$-10.31$-10.15$-11.15

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$34.03+1551.94%

  • Strong buy 1
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $17.25High $48.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-1.81 vs $-1.45
Surprise
-24.83%

CRBP news

All CRBP news

Corbus Pharmaceuticals peers

Health Care sector
CRBP peer companies
CompanyPrice% ChgMarket capCompare
INCRIntercure Ltd.3.24-7.69%$42.03Mvs CRBP
OSTXOS Therapies Incorporated0.803-2.12%$42.00Mvs CRBP
BMEABiomea Fusion Inc.0.5744-2.38%$41.75Mvs CRBP
SPROSpero Therapeutics Inc.0.742-10.20%$43.23Mvs CRBP
RLYBRallybio Corporation15.47-0.32%$43.32Mvs CRBP
MREOMereo BioPharma Group plc ADR0.26-5.45%$41.52Mvs CRBP
ELTXElicio Therapeutics Inc.1.45-3.33%$41.05Mvs CRBP
TLPHTalphera Inc.0.7852+6.25%$40.80Mvs CRBP

Indexes, lists and sector

Corbus Pharmaceuticals stock FAQ

What is Corbus Pharmaceuticals's stock price today?

CRBP last traded at $2.06 as of Nov 20, 4:00 PM EST, down 15.40% on the day. Prices are delayed at least 15 minutes.

Does Corbus Pharmaceuticals pay a dividend?

No. Corbus Pharmaceuticals does not currently pay a regular cash dividend.

Who is Corbus Pharmaceuticals's CEO?

Dr. Yuval Cohen Ph.D. is the chief executive officer of Corbus Pharmaceuticals Holdings Inc., which has about 36 employees.

Has CRBP ever split its stock?

Yes. The most recent CRBP stock split was a 1-for-30 split on Feb 14, 2023.

What is the CRBP 52-week high?

The 52-week high for CRBP is $12.88 and the 52-week low is $2.01. The stock is currently 84.0% below its high.

Compare CRBP